Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
Lilly officials said 31% of people taking Zepbound lost at least 25% of their body weight compared to 16% of study ...
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...
But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback